Off-patent Drugs Bill

Debate between Jo Stevens and Marcus Fysh

Friday 6th November 2015 Commons Chamber

[Marcus Fysh (Yeovil) (Con)]

It is a great pleasure to take part in such an important cross-party debate that has engendered such interest among leading health agencies and campaign groups, and I congratulate the hon. Member for Torfaen (Nick Thomas-Symonds) on bringing it forward.

After discussing this issue with my constituents and key stakeholders based in my constituency over the past few months, I can now say that I welcome the fact that the Bill has reached its Second Reading. I am persuaded to be a firm advocate of the proposal for the Government to step in to license and approve off-patent drugs for new uses. Support for the Bill is consistent with the advice of health organisations in my constituency, such as the Ribbon Trust, which is a partner of Breast Cancer Now. The trust was set up by a fantastic group of cancer sufferers and survivors and their families around Chard in the western part of my constituency. They do an inspiring job of looking after each other and are determined to campaign for better options and treatment.

These brave ladies and their families have convinced me of the importance for breast cancer sufferers of accessing low-cost drugs for new purposes. For example, the use of zoledronic acid would save the lives of thousands of secondary breast cancer sufferers a year. Similarly, the Treat Me Right campaign, run by the Multiple Sclerosis Society and promoted by its Yeovil and Sherborne branch, supports the Bill, as it would give 65,000 secondary progressive MS sufferers nationwide access to the first treatment that can slow the cruel disease of MS.

[Jo Stevens (Cardiff Central) (Lab)]

Of the many constituents who have written to me about this excellent Bill, two suffer from progressive MS. If the Bill becomes law, cheaper drugs would be available. Would not making this medicine available save the NHS money on the treatment of progressive diseases?

[Marcus Fysh]

That is a good point and one I will come to in a moment.

One of my Yeovil constituents, Heather Moore, wrote to me this July, asking me to vote in favour of the Bill. She wishes it to become law not only because it would give patients wider access to the benefits of new treatment options, but because it would give financial advantage to the NHS by providing some very low-cost treatments. At this time of pressure on health services from demography and budget pressure, the improvements in cost-effectiveness that could stem from the Bill are essential.

A similar private Member’s Bill, sponsored by the previous Member for Cardiff North in the last Parliament, made it to Second Reading but was regrettably stopped short of becoming law. I believe that today’s Bill outlines an even more compelling case for approval, since it specifies the need for the Government to seek licences for off-patent drugs in new indications.